Understanding pancreatic endocrine and exocrine loss in pre-type 1 diabetes
了解 1 型糖尿病前期的胰腺内分泌和外分泌丧失
基本信息
- 批准号:10461979
- 负责人:
- 金额:$ 64.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AbdomenAcinar CellAcuteAffectAgeArea Under CurveArginineAutoantibodiesAutoimmunityBeta CellBiological MarkersBlindedBody SizeBody WeightBody mass indexC-PeptideCell physiologyChildChronicClinicalComplexCustomDNADataDiabetes MellitusDiseaseDisease ProgressionEarly identificationEndocrineEnrollmentEventFastingFirst Degree RelativeFloridaFunctional disorderFundingGenetic DeterminismGenotypeGlucoseGlycosylated hemoglobin AHeterogeneityHyperglycemiaImageImmunologicsInsulinInsulin-Dependent Diabetes MellitusInterventionIslets of LangerhansLearningLipaseLongitudinal StudiesMRI ScansMagnetic Resonance ImagingMeasuresMetabolicMorphologyMulticenter StudiesNational Institute of Diabetes and Digestive and Kidney DiseasesNatural HistoryOGTTOrgan DonorOrgan SizeOrgan WeightPancreasPatientsPersonsPhenotypePhysiologicalPrevention strategyRadiology SpecialtyResearch InstituteRiskSamplingSecretory CellSeriesSerumStructure of beta Cell of isletSurrogate MarkersTestingTimeTrypsinogenUnited States National Institutes of HealthUniversitiesWeightautoimmune pathogenesisdiabetes pathogenesisdiabetes riskdisorder riskfunctional lossgenetic analysishigh riskimprovedinsulin dependent diabetes mellitus onsetisletislet cell antibodylifetime risknovelprognostic valueprogression riskradiologistresponsesex
项目摘要
For decades, type 1 diabetes (T1D) has been considered a disorder resulting from chronic autoimmune
destruction of insulin-producing pancreatic β-cells. While a broad number of intellectual advances have improved
our understanding of the natural history of T1D, significant gaps remain in the complex series of physiological
events, both immunologic and metabolic, that initiate β-cell autoimmunity, spur the loss of functional β-cell mass,
and culminate in clinical diabetes. People with a first-degree relative (FDR) with T1D have ~15-fold increased
lifetime risk of T1D. Importantly, natural history studies have informed the use of islet-associated autoantibodies
(AAb) as biomarkers to track progression to overt disease, and these biomarkers were transformative for the
field. Nevertheless, there remains significant heterogeneity in T1D progression, and additional biomarkers of
T1D risk are urgently needed. Studies by this group demonstrated that pancreas weights from organ donors with
T1D were significantly reduced, including at diabetes onset, and provided essential data using the ratio of
pancreas weight to body weight or BMI (relative pancreas volume, RPV) to normalize for subjects’ sex and age.
Yet more profound in terms of T1D pathogenesis, reductions in pancreas size were also observed in single AAb+
donors compared to autoantibody-negative (AAb-) control donors. Subsequently, a pilot cross-sectional DP3 trial
in NIH-NIDDK TrialNet (TN) subjects was completed using magnetic resonance imaging (MRI) to quantify RPV
in FDR in comparison to controls and patients with recent-onset T1D (< 1-year duration). Strikingly, a reduction
in RPV was observed in FDR without AAb (AAb-) with further reductions in RPV for FDR with single and multiple
AAb+. We hypothesize that a smaller pancreas size is predictive of T1D risk and a decline in pancreas
size over time is predictive for diabetes progression. This hypothesis will be tested at four TrialNet centers
in FDR subjects. To test our hypothesis, we will: Aim 1: Quantify pancreas volume (PV) and morphology in
FDR subjects by AAb status and test for longitudinal changes in PV. Aim 2: Correlate PV and morphology
with surrogate markers of β-cell function and mass. Aim 3: Correlate PV and morphology with surrogate
markers of acinar function. Aim 4: Perform SNP analyses for genetic determinants of pancreas size. The
successful completion of these studies will serve to expand the prognostic utility of pancreas MRI in
understanding T1D pathophysiology. Non-contrast pancreas MRI is safe and readily performed in children and
could add to biomarkers informing T1D risk predication, and potentially, progression. Endocrine-exocrine
interactions are novel and are expected to provide a new understanding of diabetes pathogenesis. Earlier
identification of subjects at highest risk for T1D progression is expected to significantly impact prevention
strategies and their successful application before the loss of functional β-cell mass is irreversible.
几十年来,1型糖尿病(T1D)一直被认为是一种慢性自身免疫引起的疾病
破坏产生胰岛素的胰腺β细胞。在大量智力进步的同时,
我们对T1D的自然历史的了解,在复杂的生理系列中仍然存在重大差距
启动β细胞自身免疫的免疫和代谢事件,刺激功能性β细胞团的丧失,
并最终发展为临床糖尿病。有一级亲属(FDR)患有T1D的人增加了约15倍
T1D的终生风险。重要的是,自然历史研究已经为胰岛相关自身抗体的使用提供了信息。
(AAB)作为追踪疾病进展的生物标记物,这些生物标记物对
菲尔德。然而,在T1D进展中仍然存在显著的异质性,并且更多的生物标志物
T1D风险是迫切需要的。该小组的研究表明,来自器官捐赠者的胰腺重量
T1D显著降低,包括在糖尿病发作时,并提供了使用
胰腺重量/体重或BMI(相对胰腺体积,RPV),以使受试者的性别和年龄正常化。
然而,在T1D发病机制方面,单一AAB+组也观察到胰腺大小缩小
供者与自身抗体阴性(AAB-)对照供者。随后,一项试点横断面DP3试验
在NIH-NIDDK TrialNet(TN)受试者中,使用磁共振成像(MRI)来量化RPV
在FDR中与对照组和新发T1D患者(病程1年)进行比较。令人惊讶的是,削减
在没有AAB的FDR中观察到RPV(AAB-),在有单个和多个FDR的FDR中RPV进一步降低
AAB+。我们假设,较小的胰腺大小预示着T1D风险和胰腺的下降
随着时间的推移,体型大小可以预测糖尿病的进展。这一假设将在四个TrialNet中心进行测试
在富兰克林·罗斯福的研究对象中。为了验证我们的假设,我们将:目标1:量化胰腺体积(PV)和形态
FDR受试者按AAB状态和PV纵向变化进行检验。目标2:将PV和形态联系起来
带有β的替代标记--细胞功能和质量。目标3:将PV和形态与代理相关
腺泡功能的标志物。目的4:对胰腺大小的遗传决定因素进行SNP分析。这个
这些研究的成功完成将有助于扩大胰腺MRI在
了解T1D病理生理学。非对比剂胰腺MRI在儿童和儿童中是安全和容易执行的
可能会增加生物标记物,告知T1D风险预测,并可能导致进展。内分泌-外分泌
相互作用是新的,有望为糖尿病的发病机制提供新的理解。早些时候
确定T1D进展的最高风险受试者预计将对预防产生重大影响
策略及其成功应用之前,功能性β细胞团的丧失是不可逆转的。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Type 1 Diabetes: A Disorder of the Exocrine and Endocrine Pancreas.
1 型糖尿病:胰腺外分泌和内分泌疾病。
- DOI:10.33696/immunology.5.177
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Bruggeman,BrittanyS;Schatz,DesmondA
- 通讯作者:Schatz,DesmondA
Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Type 1 Diabetes in Acute Pancreatitis Consortium.
- DOI:10.1097/mpa.0000000000002077
- 发表时间:2022-07-01
- 期刊:
- 影响因子:2.9
- 作者:Wasserfall, Clive;Dyer, Anne-Marie;Speake, Cate;Andersen, Dana K.;Baab, Kendall Thomas;Bellin, Melena D.;Broach, James R.;Campbell-Thompson, Martha;Chinchilli, Vernon M.;Lee, Peter J.;Park, Walter G.;Pratley, Richard E.;Saloman, Jami L.;Sims, Emily K.;Tang, Gong;Yadav, Dhiraj;Yazici, Cemal;Conwell, Darwin L.
- 通讯作者:Conwell, Darwin L.
Substance Use Affects Type 1 Diabetes Pancreas Pathology: Implications for Future Studies.
- DOI:10.3389/fendo.2021.778912
- 发表时间:2021
- 期刊:
- 影响因子:5.2
- 作者:Bruggeman BS;Campbell-Thompson M;Filipp SL;Gurka MJ;Atkinson MA;Schatz DA;Jacobsen LM
- 通讯作者:Jacobsen LM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTHA CAMPBELL-THOMPSON其他文献
MARTHA CAMPBELL-THOMPSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTHA CAMPBELL-THOMPSON', 18)}}的其他基金
Multi-omic 3D tissue maps for a Human BioMolecular Atlas
人类生物分子图谱的多组学 3D 组织图谱
- 批准号:
10685583 - 财政年份:2020
- 资助金额:
$ 64.11万 - 项目类别:
Understanding pancreatic endocrine and exocrine loss in pre-type 1 diabetes
了解 1 型糖尿病前期的胰腺内分泌和外分泌丧失
- 批准号:
10226911 - 财政年份:2020
- 资助金额:
$ 64.11万 - 项目类别:
Pathways and critical regulators of early beta-cell dysfunction in type 1 diabetes
1 型糖尿病早期 β 细胞功能障碍的途径和关键调节因子
- 批准号:
10202585 - 财政年份:2019
- 资助金额:
$ 64.11万 - 项目类别:
Pathways and critical regulators of early beta-cell dysfunction in type 1 diabetes
1 型糖尿病早期 β 细胞功能障碍的途径和关键调节因子
- 批准号:
10441263 - 财政年份:2019
- 资助金额:
$ 64.11万 - 项目类别:
Pathways and critical regulators of early beta-cell dysfunction in type 1 diabetes
1 型糖尿病早期 β 细胞功能障碍的途径和关键调节因子
- 批准号:
9802936 - 财政年份:2019
- 资助金额:
$ 64.11万 - 项目类别:
Neuromodulation-based treatment of diabetes: identifying anatomical and physiological pancreatic innervation targets
基于神经调节的糖尿病治疗:确定解剖学和生理学胰腺神经支配目标
- 批准号:
9752693 - 财政年份:2016
- 资助金额:
$ 64.11万 - 项目类别:
Defining Islet Heterogeneity Using Single Islet Transcriptomics
使用单胰岛转录组学定义胰岛异质性
- 批准号:
8812982 - 财政年份:2014
- 资助金额:
$ 64.11万 - 项目类别:
Pancreas Volume in Preclinical Type 1 Diabetes
临床前 1 型糖尿病的胰腺体积
- 批准号:
8644494 - 财政年份:2013
- 资助金额:
$ 64.11万 - 项目类别:
Leica Laser Microdissection Microscope for a Shared Resource
共享资源的徕卡激光显微切割显微镜
- 批准号:
8448032 - 财政年份:2013
- 资助金额:
$ 64.11万 - 项目类别:
相似海外基金
Regulation of acinar cell function
腺泡细胞功能的调节
- 批准号:
RGPIN-2018-06444 - 财政年份:2022
- 资助金额:
$ 64.11万 - 项目类别:
Discovery Grants Program - Individual
Regulation of acinar cell function
腺泡细胞功能的调节
- 批准号:
RGPIN-2018-06444 - 财政年份:2021
- 资助金额:
$ 64.11万 - 项目类别:
Discovery Grants Program - Individual
Regulation of acinar cell function
腺泡细胞功能的调节
- 批准号:
RGPIN-2018-06444 - 财政年份:2020
- 资助金额:
$ 64.11万 - 项目类别:
Discovery Grants Program - Individual
Elucidation of the developmental mechanism of pancreatic acinar cell metaplasia in stomach
胃胰腺腺泡细胞化生发育机制的阐明
- 批准号:
20K16985 - 财政年份:2020
- 资助金额:
$ 64.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research on carcinogenesis and cell differentiation using established human pancreatic acinar cell carcinoma cell line
利用已建立的人胰腺腺泡细胞癌细胞系进行癌发生和细胞分化的研究
- 批准号:
19K07518 - 财政年份:2019
- 资助金额:
$ 64.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Characterization of SPCA2C in acinar cell function
SPCA2C 在腺泡细胞功能中的表征
- 批准号:
539767-2019 - 财政年份:2019
- 资助金额:
$ 64.11万 - 项目类别:
University Undergraduate Student Research Awards
Regulation of acinar cell function
腺泡细胞功能的调节
- 批准号:
RGPIN-2018-06444 - 财政年份:2019
- 资助金额:
$ 64.11万 - 项目类别:
Discovery Grants Program - Individual
The study to detect early-stage pancreatic cancer based on the data from molecular biology about the atrophic acinar cell surrounding carcinoma in situ.
该研究基于原位癌周围萎缩性腺泡细胞的分子生物学数据来检测早期胰腺癌。
- 批准号:
18K07897 - 财政年份:2018
- 资助金额:
$ 64.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Regulation of acinar cell function
腺泡细胞功能的调节
- 批准号:
RGPIN-2018-06444 - 财政年份:2018
- 资助金额:
$ 64.11万 - 项目类别:
Discovery Grants Program - Individual
Investigation of the role of BRG1 in acinar cell-derived pancreatic tumorigenesis
BRG1 在腺泡细胞源性胰腺肿瘤发生中的作用研究
- 批准号:
17H06805 - 财政年份:2017
- 资助金额:
$ 64.11万 - 项目类别:
Grant-in-Aid for Research Activity Start-up